BioSpace News Archive

Even before the drug’s approval on June 7, there were cases of amyloid-related imaging abnormalities (ARIA-E), or cerebral edema, observed in the trials.

Before going for pharmaceutical jobs interviews, you should be prepared to give the best answers possible. Here are six questions you should be ready for.

If you are wondering what the butterfly effect is and how it affects COVID-19 patients, you have come to the right place. Here is everything you need to know.

Qurient Co. Ltd. (KRX: 115180), today announced that the company has entered into a clinical collaboration agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA,, for clinical study of Q702, a triple inhibitor of Axl/Mer/CSF1R) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

Certara, Inc., a global leader in biosimulation, announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per share.

Synlogic, Inc. (Nasdaq: SYBX), today announced presentation of interim data from the company’s Phase 2 SynPheny-1 clinical trial showing that treatment with the investigational Synthetic BioticTM medicine SYNB1618 resulted in significant reductions in plasma phenylalanine (Phe) levels in patients with phenylketonuria (PKU).

Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2021.

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, announces that the Company entered into a new loan structure with Kreos Capital.

On November 17, 2021, Simcere Pharmaceutical Group Limited announced that the company has reached collaboration agreement with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, to develop novel antiviral drugs for COVID-19.

Obseva SA announced that the New Drug Application for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted for review by the United States Food and Drug Administration.